Merck & Co.
Merck & Co. (MSD) scientists joined the lab on an electroaffinity labelling platform for target identification and on a scalable total synthesis of saxitoxin, bringing world-class process and chemical biology expertise to both.
Rahway, New Jersey · Known as MSD outside the United States and Canada.
- Papers together
- 2
- Years
- 2023–2025
- Co-authors
- 8
All 2 papers with Merck & Co.
-
Scalable Total Synthesis of Saxitoxin and Related Natural Products
- Merck & Co. Christopher K. Prier, Kai-Jiong Xiao
- Debut Biotechnology Christopher K. Prier
-
An Electroaffinity Labelling Platform for Chemoproteomic-Based Target Identification
- Merck & Co. Aleksandra Olow, Keun Ah Ryu, La-Tonya A. Adams, Lee R. Roberts, Olugbeminiyi Fadeyi, Rob Oslund
- InduPro Therapeutics Olugbeminiyi Fadeyi, Rob Oslund
No papers match these filters.
Our co-authors at Merck & Co.
La-Tonya A. Adams · Olugbeminiyi Fadeyi · Aleksandra Olow · Rob Oslund · Christopher K. Prier · Lee R. Roberts · Keun Ah Ryu · Kai-Jiong Xiao
Some of these papers were shared with 2 other partners: Debut Biotechnology, InduPro Therapeutics.
More partners
Enamine
HitGen Hongene Biotech Hongene Biotech IKA IKA InduPro Therapeutics InduPro Therapeutics
KULR Technology RQx Pharmaceuticals RQx Pharmaceuticals Socrates Biosciences Socrates Biosciences The Medicines Company The Medicines Company Interested in collaborating with the Baran lab?
If your team has a problem that matters, a molecule no one can make, a reaction that will not scale, a reagent that should exist, we would love to hear about it.
Email Philor write to pbaran@scripps.edu

